JP2024543259A5 - - Google Patents

Info

Publication number
JP2024543259A5
JP2024543259A5 JP2024531268A JP2024531268A JP2024543259A5 JP 2024543259 A5 JP2024543259 A5 JP 2024543259A5 JP 2024531268 A JP2024531268 A JP 2024531268A JP 2024531268 A JP2024531268 A JP 2024531268A JP 2024543259 A5 JP2024543259 A5 JP 2024543259A5
Authority
JP
Japan
Application number
JP2024531268A
Other languages
Japanese (ja)
Other versions
JP2024543259A (ja
JPWO2023092180A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2022/051405 external-priority patent/WO2023092180A1/en
Publication of JP2024543259A publication Critical patent/JP2024543259A/ja
Publication of JPWO2023092180A5 publication Critical patent/JPWO2023092180A5/ja
Publication of JP2024543259A5 publication Critical patent/JP2024543259A5/ja
Pending legal-status Critical Current

Links

JP2024531268A 2021-11-24 2022-11-24 ＳＡＲＳ－ＣｏＶ－２感染を治療する方法 Pending JP2024543259A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021903789A AU2021903789A0 (en) 2021-11-24 Methods of treating sars-cov-2 infection
AU2021903789 2021-11-24
PCT/AU2022/051405 WO2023092180A1 (en) 2021-11-24 2022-11-24 Methods of treating sars-cov-2 infection

Publications (3)

Publication Number Publication Date
JP2024543259A JP2024543259A (ja) 2024-11-20
JPWO2023092180A5 JPWO2023092180A5 (https=) 2025-11-25
JP2024543259A5 true JP2024543259A5 (https=) 2025-11-25

Family

ID=86538440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531268A Pending JP2024543259A (ja) 2021-11-24 2022-11-24 ＳＡＲＳ－ＣｏＶ－２感染を治療する方法

Country Status (8)

Country Link
US (1) US20250009713A1 (https=)
EP (1) EP4436576A4 (https=)
JP (1) JP2024543259A (https=)
KR (1) KR20240110039A (https=)
CN (1) CN118574614A (https=)
AU (1) AU2022399231A1 (https=)
CA (1) CA3238183A1 (https=)
WO (1) WO2023092180A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260100B (zh) * 2022-08-08 2023-12-12 赛诺瑞生物医药技术(无锡)有限公司 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596107A (en) * 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
ES2563477T3 (es) * 2007-08-03 2016-03-15 Biotron Limited Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
SG11201907034PA (en) * 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
US20220409587A1 (en) * 2019-11-26 2022-12-29 Biotron Limited Methods of treating hiv-1 infection
US11660307B2 (en) * 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
WO2021207049A1 (en) * 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs

Similar Documents

Publication Publication Date Title
CL2025003864A1 (es) Proteínas de fusión de una o varias citocinas y sus usos.
CL2025003198A1 (es) Tecnologías dirigidas a estados celulares
JP2024543259A5 (https=)
CL2026000430A1 (es) Fuente de energía renovable usando procesos y sistemas de filtración impulsada por presión
BR202022000931U2 (https=)
BY13155U (https=)
BY13159U (https=)
BY13149U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)
BY13167U (https=)
BY13166U (https=)
BY13165U (https=)
BY13164U (https=)
BY13150U (https=)
BY13163U (https=)
BY13162U (https=)
BY13145U (https=)
BY13160U (https=)
BY13176U (https=)
BY13158U (https=)
BY13157U (https=)
BY13156U (https=)
CN307046860S (https=)